Progress, Discovery, Updates

Follow ImmunoShield’s latest company developments, research milestones, and external engagement.

About the tech

“Hydrogel injection molding capitalizes on the reproducibility, efficiency, and scalability of the injection molding process, and we adapt this technique to biofabrication using a library of natural and synthetic hydrogels with varied crosslinking chemistries and kinetics.”

Amy E. Emerson, Alec B. McCall, Sarah R. Brady, Emily M. Slaby, Jessica D. Weaver; Hydrogel Injection Molding to Generate Complex Cell Encapsulation Geometries. ACS Biomater. Sci. Eng. 12 September 2022; 8 (9): 4002–4013. https://doi.org/10.1021/acsbiomaterials.2c00640

View Article

How it Works

Hydrogel injection molded complex macroencapsulation device geometry improves long-term cell therapy viability and function in the rat omentum transplant site

  • Amy E. Emerson , Quincy Lyons , Matthew W. Becker , Keven Sepulveda , Shivani C. Hiremath , Sarah R. Brady , Chishiba Chilimba , Jessica D. Weaver
Read Article

LinkedIn

Most Recent

Linked In

Check out what's new with ImmunoShield Therapeutics by visiting our LinkedIn

Click on the icon below for more...

Linkedin
Brochure of the Technology

Hydrogel Injection Molding is more than a technology, it’s the heart of our mission at ImmunoShield Therapeutics.

Linkedin
The Cells

The biology is now proven. The engineering challenge is clear. That’s where ImmunoShield is focused.

Linkedin
A New Approach

Shifting from previously tried methods to a revolutionary hydrogel macroencapsulation, if we can protect the cells, we can help unlock what this field has always promised.

Linkedin

Building Toward Meaningful Therapeutic Progress

ImmunoShield is advancing a focused development strategy centered on high-value immune-mediated disease opportunities where precision can make a real difference.

What's Next

Large Animal Studies
  • $1.8M Phase II SBIR Award
  • Recently awarded
    • Two years of funding for studying cell encapsulation technology in a large animal model
University of Miami Partnership
  • Partnering with University of Miami Diabetes Research Institute
  • World leader in cure-focused research for diabetes
Current Focus
  • Seeking funding to round out studies with immune tolerance validation
Large Animal Studies
  • Moving one step closer to making the technologies accessible to the type 1 diabetes comunity

Milestones Achieved

NSF Innovation Corps
  • Completed intensive customer discovery program, validating market need through 70+ industry interviews
Technology License
  • Secured exclusive license for foundational IP from leading research institution
NIH Phase I SBIR
  • $300K award for proof-of-concept validation in small animal models
Flinn Foundation Award
  • Bioscience Entrepreneurship Award recognizing commercial potential
NIH Phase II SBIR – $1.8M
  • Recently awarded for large animal validation studies with University of Miami Diabetes Research Institute

What This Means

Our development efforts are guided by a disciplined view of translational science: choose the right target, define the right patient need, and build evidence that supports real-world therapeutic value. Each program is selected not only for scientific promise, but for its potential to address major gaps in care.